This site is intended for healthcare professionals
Multiple Sclerosis (MS) Learning Zone
Declaration of sponsorship Novartis Pharma AG

Treatment advances in MS

Declaration of sponsorship Novartis Pharma AG
Read time: 50 mins
Last updated:25th Oct 2022
Published:22nd Dec 2021

Treatment advances in multiple sclerosis

Choosing the right treatment option at the right time is critical for managing multiple sclerosis (MS).

  • This section summarises recent advances in high-efficacy therapies (HET) for relapsing-remitting MS [RRMS] and secondary progressive MS [SPMS])
  • There has been a conceptual shift in understanding the immune pathology of MS – learn about the effects of this shift on disease-modifying therapies for MS

Traditionally, HETs have been used following a platform of disease-modifying therapies (DMT) which have resulted in suboptimal outcomes1.

Continue to read more about recent advances in high-efficacy therapies for relapsing-remitting MS and secondary progressive MS

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Freedman MS, Selchen D, Prat A, Giacomini PS. Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. Canadian Journal of Neurological Sciences. 2018;45(5):489-503.
  2. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019;321(2):175-187.
  3. Gartner J, Hauser S, Bar-Or A, Montalban X, Cohen J, Cross AH, et al. Benefit-risk of ofatumumab in treatment-naïve early relapsing multiple sclerosis patients. Multiple Sclerosis Journal. 2020;26:210-210.
  4. Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2016;9:S5-S48.
  5. He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. The Lancet Neurology. 2020;19(4):307-316.
  6. Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology. 2019;266(5):1182-1193.
  7. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine. 2020;383(6):546-557.
  8. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet. 2018;391(10127):1263-1273.
  9. Schmierer K, Sørensen PS, Baker D. Highly effective disease-modifying treatment as initial MS therapy. Current opinion in neurology. 2021;34(3):286-294.
  10. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. American Journal of Medicine. 2020;133(12):1380-1390.e1382.
  11. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Annals of Neurology. 2006;60(1):12-21.
  12. Van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial. Neurology. 1997;49(2):351-357.
  13. Hauser SL. The Charcot Lecture | Beating MS: A story of B cells, with twists and turns. Multiple Sclerosis Journal. 2015;21(1):8-21.
  14. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine. 2017;376(3):221-234.
  15. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis. New England Journal of Medicine. 2008;358(7):676-688.
  16. Riederer F. Ocrelizumab versus placebo in primary progressive multiple sclerosis. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2017;18(1):30-31.
  17. Cox AL, Thompson SAJ, Jones JL, Robertson VH, Hale G, Waldmann H, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. European Journal of Immunology. 2005;35(11):3332-3342.
  18. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. The Lancet. 2012;380(9856):1819-1828.
  19. Beutler E. Cladribine (2-chlorodeoxyadenosine). The Lancet. 1992;340(8825):952-956.
  20. Rice GPA, Filippi M, Comi G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Neurology. 2000;54(5):1145-1155.
  21. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2010;362(5):416-426.
  22. Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, et al. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary. Neurodegener Dis Manag. 2022;12(6):303-310.
  23. NCT03369665. Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS). Available at: https://clinicaltrials.gov/ct2/show/NCT03369665. Accessed 25 October 2022.
  24. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Neurology. 2014;13(6):545-556.
  25. Lamb YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022;82(3):323-334.
  26. Gibiansky E, Petry C, Mercier F, Günther A, Herman A, Kappos L, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. British Journal of Clinical Pharmacology. 2021;87(6):2511-2520.
  27. Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, et al. Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091). Neurology. 2019;92(15 Supplement):P3.2-091.
  28. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2006;354(9):899-910.
  29. Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. The Lancet Neurology. 2017;16(11):925-933.
  30. Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M, et al. Use of natalizumab in persons with multiple sclerosis: 2022 update. Multiple Sclerosis and Related Disorders. 2022;65.
  31. Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Prefer Adherence. 2022;16:1307-1319.
  32. Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, et al. Optimizing treatment success in multiple sclerosis. Journal of Neurology. 2016;263:1053-1065.
  33. Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal. 2022;28(10):1576-1590.
  34. Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. British Journal of Pharmacology. 2016;173(11):1778-1792.
  35. Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. The Lancet Neurology. 2019;18(11):1021-1033.
  36. DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, et al. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Mult Scler Relat Disord. 2021;48:102673.
  37. Fronza M, Lorefice L, Frau J, Cocco E. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. Drug Des Devel Ther. 2021;15:1993-2004.
  38. D’Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: A potential treatment for multiple sclerosis and other immune-mediated diseases. Therapeutic Advances in Chronic Disease. 2016;7(1):18-33.
  39. Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. Journal of Pharmacology and Experimental Therapeutics. 2011;337(2):547-556.
  40. Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, et al. Ponesimod Compared with Teriflunomide in Patients with Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurology. 2021;78(5):558-567.
  41. NCT03232073. Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis (OPTIMUM-LT). Available at: https://clinicaltrials.gov/ct2/show/NCT03232073. Accessed 25 October 2022.
  42. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. Journal of Pharmacology and Experimental Therapeutics. 2012;341(1):274-284.
  43. Mills EA, Mao-Draayer Y. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Multiple Sclerosis Journal. 2018;24(8):1014-1022.
  44. Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Mokliatchouk O, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Multiple Sclerosis Journal. 2022;28(5):801-816.
  45. Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011;25(6):491-502.
  46. Hughes R, Francis G. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology. 2001;56(12):1628-1636.
  47. Kappos L, Kuhle J, Multanen J, Kremenchutzky M, Di Cantogno EV, Cornelisse P, et al. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. Journal of Neurology, Neurosurgery and Psychiatry. 2015;86(11):1202-1207.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: